David R Lilenquist
3 Papers
David R Lilenquist is an academic researcher. The author has contributed to research in topics: Internal medicine & Diabetes mellitus. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Improved Glycemia with Hybrid Closed-Loop (HCL) Versus Continuous Subcutaneous Insulin Infusion (CSII) Therapy: Results from a Randomized Controlled Trial.
Satish K. Garg,George Grunberger,Ruth S. Weinstock,Margaret L. Lawson,Irl B. Hirsch,Linda A. DiMeglio,Rodica Pop-Busui,Athena Philis-Tsimikas,Mark Kipnes,David R Lilenquist,Ronald L. Brazg,Yogish C. Kudva,Bruce A. Buckingham,Janet B. McGill,Anders E. Carlson,Amy Criego,Mark P. Christiansen,Kevin B Kaiserman,K Griffin,Gregory P. Forlenza,Bruce W. Bode,Robert H. Slover,Ashleigh Keiter,Chenxiao Ling,B.A. Marinos,Toni L. Cordero,John J. Shin,Scott W. Lee,Andrew S. Rhinehart,Robert A. Vigersky +29 more
TL;DR: In this article , the authors evaluated the safety and effectiveness of MiniMed 670G hybrid closed loop in comparison with continuous subcutaneous insulin infusion (CSII) therapy for six months, in persons with Type 1 diabetes (T1D).
32
Accuracy of Three Commercial Home-Use HbA1c Tests.
Laura M. Jacobsen,Laura E. Bocchino,John Lum,Craig Kollman,Victoria Barnes-Lomen,Mark Sulik,Michael J. Haller,Bruce W. Bode,Joseph T. Cernich,Anthony A. Killeen,Uttam Garg,David R Lilenquist,Janey Adams,Margaret Clements,Deanna Gabrielson,Terri Kang Johnson,Mark A. Clements,Roy W. Beck +17 more
TL;DR: None of the commercial home-use HbA1c tests produced the National Glycohemoglobin Standardization Program goal of ≥90% measurements within 5% of a DCCT venous reference, however, the Home Access product performed substantially better than the CoreMedica or A1cNow+ products.
4
Safety and glycemic outcomes during the MiniMed™ advanced hybrid closed-loop (AHCL) system pivotal trial in children and adolescents with type 1 diabetes.
Catherine Pihoker,Dorothy I. Shulman,Gregory P. Forlenza,Kevin B Kaiserman,Jennifer L. Sherr,James R Thasher,Bruce A. Buckingham,M. S. Kipnes,Bruce W. Bode,Anders E. Carlson,Scott Lee,Kashif Latif,David R Lilenquist,Robert H. Slover,Zheng Dai,Fang Niu,John J. Shin,R. Jonkers,Anirban Roy,Benyamin Grosman,Melissa Vella,Toni L. Cordero,Jennifer McVean,Andrew S. Rhinehart,Robert A. Vigersky +24 more
TL;DR: In children and adolescents with T1D, MiniMed™ AHCL system use was safe, A1C was lower, and TIR was increased, all of which met recommended glycemic targets.